secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oyster Point Pharma, Inc. (—)
CIK:        0001720725
Form:       8-K/A
Filed at:   2023-01-13T23:59:59+00:00
Accession:  0001193125-23-008477
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.02, 2.01, 3.01, 3.03, 5.03, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oyster Point corrects OrbiMed loan payoff to $112.2M (was $298.8M); Viatris merger closes
--------------------------------------------------------------------------------

- Aggregate payoff for OrbiMed Credit Agreement corrected to ~$112.2M; prior filing incorrectly stated ~$298.8M.
- Viatris subsidiary acquired all OYST shares for $11.00 cash plus up to $2.00 CVR per share; total consideration ~$298.8M (excl. CVRs).
- Merger closed Jan 3, 2023; shares delisted from Nasdaq; board replaced with Viatris appointees.
- Amended certificate of incorporation and bylaws effective at merger close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720725/000119312523008477/0001193125-23-008477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720725/000119312523008477/d773804d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-008477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer